Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | MELK | Q14680 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541747 | 1.00 | CALML3 (0.53) | CALML3MAOAMAOBTLR9TLR8 | |
| SCHEMBL3818352 | 0.95 | CALML3 (0.51) | CALML3MAOAMAOBTLR9TLR8 | |
| SCHEMBL542051 | 0.95 | CALML3 (0.51) | CALML3MAOAMAOBTLR9TLR8 | |
| SCHEMBL10033721 | 0.87 | MAOA (0.57) | CALML3MAOAMAOBF10 | |
| SCHEMBL10033753 | 0.84 | MAOA (0.54) | CALML3MAOAMAOBF10 | |
| SCHEMBL542046 | 0.83 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL542047 | 0.83 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL17769285 | 0.82 | CALML3 (0.52) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| Hydrochloric Acid SCHEMBL17769284 | 0.82 | CALML3 (0.52) | CALML3MAOAMAOBCYP2C19CYP2C9 | |
| SCHEMBL10033726 | 0.82 | MAOA (0.56) | CALML3MAOAMAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124623-B2 | 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-02-28 | — | — | US | disclosed |
| EP-2086968-B1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-10-01 | — | — | US | disclosed |
| EP-2086968-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008056335-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247578-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE-DERIVATIVES AND THEIR USES AS ANTIBACTERIALS | OGFOD1, OXGR1, ODC1 | CALML3 3066/4885MAOA 447/4885MAOB 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.